Qigong For PPSP In Breast Cancer Pain In Breast Cancer Survivors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02848989|
Recruitment Status : Active, not recruiting
First Posted : July 29, 2016
Last Update Posted : August 28, 2018
Studies have shown that on-going pain following breast surgery is common and may limit the ability to participate in physical activity, cause tiredness, difficulty in daily chores/activities as well as other problems.
This study is evaluating whether participating in a 12-week Qigong program (pronounced chee kung), an exercise program that involves gentle movements combined with breathing/relaxation techniques, also known as mind-body exercise, leads to improvement of pain, physical function, and quality of life among breast cancer survivors that have significant pain following surgery.
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer Surgery Pain Breast Cancer Stage 0-III Breast Cancer||Other: Qigong Mind-Body Exercise||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||21 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||Qigong Mind-Body Exercise For Persistent Post-Surgical Pain In Breast Cancer Survivors: A Pilot Study|
|Actual Study Start Date :||April 4, 2017|
|Actual Primary Completion Date :||March 14, 2018|
|Estimated Study Completion Date :||April 2021|
Experimental: Qigong Mind-Body Exercise (QMBE)
After the screening procedures confirm that you are eligible to participate in the research study:
Other: Qigong Mind-Body Exercise
An exercise program that involves gentle movements combined with breathing/relaxation techniques
- Rate of completion of QMBE intervention [ Time Frame: 12 months ]Complete recruitment of target enrollment of 21 participants within 12 month timeframe.
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: 6 months ]Total number of adverse events sustained from participation in QMBE will be collected for each participant through home practice logs for at home QMBE participation and instructors will report any adverse events that occur during QMBE class on attendance logs. Any adverse events observed will be evaluated according to the DFCI/Harvard Cancer Center guidelines. The study will be considered safe if zero adverse events are observed/reported from participation in prescribed QMBE classes and/or at home practice.
- Quality of life [ Time Frame: 6 months ]QOL will be assessed using the Functional Assessment of Cancer Therapy Breast Symptom Index (FACT-B+4). This instrument consists of 42 items that measure physical, emotional, social and functional well-being, as well as breast cancer specific symptomology associated with upper extremity dysfunction.
- Degree of Pain [ Time Frame: 6 months ]Degree of pain will be measured by the Brief Pain Inventory Short Form (BPI SF) and a Pain Medication Log.21 The BPI SF consists of 9 items that measure the severity of pain, impact of pain on daily function, location of pain, pain medications and amount of pain relief in the past 24 hours or the past week. Reliability coefficients for the BPI Severity and Interference scales ranged from .82 to .95
- Grip Strength [ Time Frame: 3 months ]Grip strength of both hands will be assessed using the Jamar® Hand Dynamometer. Measurement will be recorded to the nearest 0.5 kg, and repeated an average of three times
- Gait & Postural Control [ Time Frame: 3 months ]Gait & postural control will be kinematically assessed during standing and walking using an 8-camera motion analysis system (Vicon 512, Oxford, UK) using standard protocols employed in prior mind-body studies as well as clinical evaluations for both children and adults with walking abnormalities due to mobility-limiting conditions, at the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital.
- Pain Catastrophizing [ Time Frame: 3 months ]Pain catastrophizing scale will be used to assess catastrophic thinking associated with pain. This instrument consists of 13 items that measure rumination, magnification, and helplessness related to pain.
- Shoulder Strength [ Time Frame: 3 months ]Will be assessed using manual muscle testing (MMT).
- Range of Motion [ Time Frame: 3 months ]Will be assessed using standard goniometric measurement.
- Fatigue [ Time Frame: 3 months ]Fatigue will be assessed by the 13 item FACIT-F fatigue subscale. This validated instrument measures the intensity of fatigue experienced during the 7 days before questionnaire administration.
- Self-esteem [ Time Frame: 3 months ]Self-esteem will be measured by the 10 item Rosenberg Self-Esteem Scale. This validated instrument measures global self-worth by measuring both positive and negative feelings about the self.
- Anxiety & Depression [ Time Frame: 3 months ]Anxiety and depression will be measured by the Hospital and Anxiety and Depression Scale (HADS). This validated instrument consists of 14 items that measure current feelings of anxiety and depression.
- Stress Levels [ Time Frame: 3 months ]Stress levels will be measured by the 10 item Perceived Stress Scale (PSS). This validated instrument measures the degree to which situations in one's life are appraised as stressful.
- Mindfulness [ Time Frame: 3 months ]Mindfulness will be assessed using the Multidimensional Assessment of Interoceptive Awareness Scale (MAIA). This 32-item instrument measures a patient's bodily and emotional awareness and ability to self-regulate these factors.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02848989
|United States, Massachusetts|
|Dana-Farber Cancer Institute|
|Boston, Massachusetts, United States, 02215|
|Principal Investigator:||Jennifer A Ligibel, MD||Dana-Farber Cancer Institute|